# Outcomes of oncoplastic breast surgery in Bangladesh

#### **Dr Hasan Shahriar Kallol**

MBBS (DMC) FCPS (Surgery) MS (Surgical Oncology) MRCPS (Glasgow) FACS (USA) Clinical Fellow (Surgical Oncology), National Cancer Centre Singapore



Assistant Professor Department of Surgical Oncology National Institute of Cancer Research & Hospital



## Introduction

• For a century, mastectomy (Mx) was proven as effective therapy for breast cancer.



breast conserving surgery (BCS) and radiotherapy (RT)

similar disease free, distant disease free and overall 5-year survival

#### Issues to be considered



• Cosmetic outcome

• Quality of life

EPIDEMIOLOGY



#### Very low local recurrence rates after breast-conserving therapy: analysis of 8485 patients treated over a 28-year period

S. C. J. Bosma<sup>1</sup><sup>(1)</sup> · F. van der Leij<sup>1</sup> · E. van Werkhoven<sup>2</sup> · H. Bartelink<sup>1</sup> · J. Wesseling<sup>3</sup> · S. Linn<sup>4,5</sup> · E. J. Rutgers<sup>6</sup> · M. J. van de Vijver<sup>7</sup> · P. H. M. Elkhuizen<sup>1</sup>

- 8485 consecutive patients with early invasive breast cancer treated with BCT between 1980 and 2008 analyzed
- 80 % had tumour free margin
- 8 % with a more than focally tumor-positive resection margin.

The 5- and 10-year Ipsilateral breast tumor recurrence (IBTR) - 2 %, 5 %

**Distant metastases** - 11 % , 18 %

**OS** - 91 % , 77 %



#### **Comparison of breast-conserving surgery with mastectomy in locally advanced breast cancer after good response to neoadjuvant chemotherapy**

A PRISMA-compliant systematic review and meta-analysis

Yixuan Sun<sup>a</sup>, Mingjuan Liao, MD, PhD<sup>b</sup>, Liu He, MD<sup>c,\*</sup>, Chenfang Zhu, MD, PhD<sup>c,\*</sup>



- Patients with good response to NACT showed no significant difference in LR and DR
- A lower distant recurrence (OR=0.51; 95% CI: 0.42–0.63; P<.01), a higher DFS (OR=2.35; 95% CI: 1.84 to 3.01, P<.01) and a higher OS (OR=2.12; 95% CI: 1.51 to 2.98, P<.01) in BCS compared with MT.</li>

BCS was a safe surgery for patients with LABC who had good response to NACT

#### Issues to be considered









clear risk of breast deformity when excision volume of breast tissue is more than 20%

Noguchi M et al. Oncoplastic breast conserving surgery: Volume replacement vs. volume displacement. Eur J Surg Oncol 2016;42(7):926–34

## oncoplastic breast surgery

oncological clearance

plastic surgical technique

achieve wider excision margins without compromising the cosmetic outcomes

## When

- stage 1 and 2 breast cancer.
- good response to neo adjuvant chemotherapy (NACT) locally advanced breast cancers (LABC) can be treated with OBS

Breast size in relationship to tumor size

Tumor size, location, and nodal status all play a role in decision making



The choice of technique is dependent on a number of factors

- the extent of resection
- position of the tumour
- timing of surgery
- experience of the surgeon and
- expectations of the patient

• The surgical procedures of OBS varies from quadrant to quadrant

Clough KB et al. Improving Breast Cancer Surgery: A Classification and Quadrant per Quadrant Atlas for Oncoplastic Surgery. Ann Surg Oncol. 2010;17:1375–91.

#### **TABLE 1 Oncoplastic decision guide Criteria**

	Level I	Level II
Maximum excision volume ratio	20%	20–50%
Requirement of skin excision for reshaping	No	Yes
Mammoplasty	No	Yes
Glandular characteristics	Dense	Dense or fatty

## How



Upper quadrant junction:

Fig : Quadrant-perquadrant atlas of oncoplastic techniques

Lower quadrant junction: superior pedicle mammoplasty

#### Clough KB et al. BJS 2012; 99: 1389 - 1395

#### V Mammoplasty for lower inner quadrant (7-8 o' clock)



2

#### V mammoplasty







### J mammoplasty



Lower outer quadrant: J mammoplasty









#### Hemi batwing technique

#### 12 o clock tumour at Rt breast







#### **Batwing technique**







## Wire guided wide local excision with crescentic mammoplasty

#### IDC, ypT1 N0 (0/7) Mx , All margin clear













#### **Round block mammoplasty**







#### **Round block mammoplasty**

#### yc T1 N1 Mx











#### Round block mammoplasty











#### Crescentic mammoplasty

#### © Dr Hasan Shahriar Kallol





#### 12 months after surgery, chemo and radiation











Superior pole tumour : Post op









#### Superior pole tumour : Post RT

A case of unplanned lumpectomy with post op wound infection



HPR – IDC, no comment on margin status



#### Managed by Oncoplastic breast surgery Parellalogram technique





### If the tumour is not palpable



### Marker clip



## Hydrogel marker clip placed under US guidance





#### Hooked wire localization





#### Specimen x-ray after wire guided excision





#### **Oncoplastic breast surgery**



## 3.5 cm tumour at lt. breast, TNBC



#### **Oncoplastic breast surgery**





## Wire guided excision with Round block mammoplasty


## Specimen x-ray





## **Appearance after 3 months**







Check for updates

#### Comparison of Oncoplastic Breast-Conserving Surgery and Breast-Conserving Surgery Alone: A Meta-Analysis

Jun-Ying Chen<sup>1,2,3,\*</sup>, Yi-Jie Huang<sup>4,\*</sup>, Liu-Lu Zhang<sup>5</sup>, Ci-Qiu Yang<sup>5</sup>, Kun Wang<sup>5</sup>

3,789 patients<br/>11 studies2,691 patients in the BCS-alone group1,098 patients in the BCS plus OPS group

• better cosmesis

OPS gave actually better outcome than BCS alone

- re-excision rate was significantly lower in the BCS plus OPS group (RR, 0.66; 95% CI, 0.48–0.90; p=0.009)
- results were close for both the local (RR, 1.14; 95% Cl, 0.82–1.59; p=0.442) and distal recurrence rates (RR, 1.02; 95% Cl, 0.79–1.32; p=0.856)
- similar OS (hazard ratio [HR], 1.14; 95% CI, 0.76–1.69; p=0.527) and DFS (HR, 1.19; 95% CI, 0.96–1.49; p=0.112)

# **Bangladesh perspective**

low local recurrence rates with equivalent or better survival of patients after BCS

routine approach for early breast cancers



#### in our part of the world the rate is as low as 5 – 23%

(Ali, Somashekhar and Kumar N, 2018; Rahman, 2020)

Breast cancer is the highest prevalent female cancer in

Bangladesh.

Globocan data

NICRH data

(Paul TK *et al*, 2015)

increase of awareness



demand of breast conservation more than before.

• To standardize the OPS



necessity for **widespread training** of this procedure around

reduce mastectomy rate

physical, psychological and
financial impact of mastectomy.

• Type of Study

prospective observational study

Period of Study

from March 2021 to June 2022

Place of Study

Department of Surgical Oncology, NICRH

Study Population

Patients with breast cancer who underwent OPS at NICRH during the study period with valid documents

#### Sampling Method

consecutive purposive sampling

## **Eligibility Criteria**

## Inclusion criteria

- All patients, irrespective of age, admitted for surgical treatment of breast cancer willing to have Oncoplastic breast surgery
- Patients with early and locally advanced breast cancers which included clinical stage T1N0/T1N1, T2N0/T2N1, T3N0/T3N1 (as per AJCC TNM staging)
- Patients having either surgery as initial treatment or surgery after neoadjuvant therapy

## **Exclusion Criteria**

- Male breast cancer patient.
- Patients underwent mastectomy.
- Patients with recurrent breast cancers.
- Patients having distant metastases.
- Patients underwent only palliative surgical treatment.
- Patients not willing or fit candidate to take radiotherapy.

# Results

#### The median age of the patients was 40 years (range: 26 to 62 years)



#### Fig 3: Age distribution

Table 2: Family monthly income by category (n = 48)

Variablas	Frequency	Percent
variables	<b>(n)</b>	(%)
< = 10000 taka	20	41.7
>10000 - 20000 taka	21	43.8
>20000 taka	7	14.6

#### Table 3: Menstrual status (n = 48)

Variables	Frequency	Percent
Vallables	(n = 48)	(%)
premenopausal	23	47.9
artificial menopause	16	33.3
post-menopausal	9	18.8



#### Fig 4: Family history of breast cancer



#### Fig 5: Comorbidity type

Eighteen patients (37.5%) had some sorts of comorbidities including diabetes, hypertension, ischemic heart disease, chronic obstructive pulmonary disease or chronic kidney disease. Four of those have more than one comorbidity.

#### Table 5: BMI by category (n = 48)

Variables	Frequency (n)	Percent (%)
underweight <18.5	1	2.1
normal (18.5- 24.9)	19	39.6
overweight (25-29.9)	18	37.5
obese (>30)	10	20.8

Mean BMI of the patients were 26.78 + 4.28 kg/m2.

#### Table 6: Distribution of patients according to tumour characteristics (n = 48)

Variable	Category	Number (n )	Percentage(%)	
Site of tumour	UOQ	26	54.2	
	UIQ	14	29.2	
	LOQ	7	14.6	
	LIQ	1	2.1	
	UOQ	26	54.2	
Clinical T Stage	T1	6	12.5	
	T2	38	79.2	
	Т3	4	8.3	
Grade of tumour	1	1	2.1	
	2	43	89.6	
	3	4	8.3	

## Table 7: Distribution of patients according to receptor status (n = 48)

Variable	Frequency	Percentage (%)
	(n )	
Hormone receptor (+)ve	12	25
HER2 (+)ve	11	22.4
HER2 equivocal	4	8.3
TNBC	21	43.8

# Table 8: Distribution of patients according to clinical staging at presentation (n = 48)

Variable	Category	Number (n)	Percentage (%)
Clinical T Stage (cT)	T1	6	12.5
	<b>T2</b>	38	79.2
	T3	4	8.3
Clinical N Stage (cN)	NO	10	20.8
	N1	38	79.2

At presentation median clinical size of the tumour was 29 mm (Range: 10 – 60 mm).



#### Fig 6: Distribution of patients receiving neoadjuvant chemotherapy

# Table 9: Distribution of patients according to clinical staging after NACT (n = 34)

Variable	Category	Number (n)	Percentage (%)
Clinical T Stage	ТО	5	15.2
after NACT (ycT)	T1	19	57.6
	T2	8	24.2
	Т3	1	3.0
Clinical N Stage (ycN)	NO	14	41.2
	N1	20	58.8

#### Table 10: Distribution of patients by breast procedure (n = 48)

Variable	Frequency (n)	Percent (%)
WLE with round block mammoplasty	10	20.8
WLE with medial mammoplasty	1	2.1
WLE with hemibatwing	4	8.3
WLE with batwing	1	2.1
WLE with J mammoplasty	1	2.1
WLE with omega mammoplasty	2	4.2
WLE only along with volume displacement	11	22.9
Cavity shaving	3	6.3

Variable	Frequency (n)	Percent (%)
WLE with crescentic mammoplasty	3	6.3
WLE with "V" mammoplasty	1	2.1
WLE with Parallaelogram	3	6.3
WLE with Matrix rotation flap	2	4.2
WLE with transposition flap	1	2.1
WLE with LICAP flap	1	2.1
WLE with Lateral mammoplasty	3	6.3
WLE with key hole mammoplasty	1	2.1



#### Fig 9: Name of axillary procedures (n = 48)



Fig 10: Pathological T stage

Mean pathological size of tumour was 20.38 <u>+</u> 11.54 mm.

All the patients got pathological clear margin (100 %) . The mean distance of margin clearance was 15.05 (SD  $\pm$  7.68) mm

#### Fig 11: Pathological nodal stage (n=48)



- Mean number of nodes yielded in SLNB was 3.30 + 1.7 (n = 10).
- The range of positive lymph nodes after SLNB was 0 to 1.
- Mean number of nodes yielded after AC was 9.27 <u>+</u> 1.77.
- The mean of positive lymph nodes after AC was 1.76 <u>+</u> 1.76.

#### Table 11: Response to NACT as per RECIST criteria (n = 34)

Mariablaa	Frequency	Percent
variables	(n)	(%)
complete	3	6.3
partial	26	54.2
stable	3	6.3
progressive	2	4.2

Median duration of procedures was 100 minutes (range of 55 to 180 minutes).

# Table 12: Post op pain in day 1 and day 3 (by numerical rating scale, from 0 to 10) (n = 48)

Post-operative pain in day	Score	Frequency (n)	Percent (%)
01	1-5	31	64.6
	6-10	17	35.4
03	1-5	44	91.66
	6-10	4	8.3

The median score of post-operative pain at day 1 and day 3 were 5 (range: 3-8) and 2 (range: 1-6) respectively. The mean length of post-operative hospital stay was 3 days (Range: 1-6 days).

#### **Fig 12: Post-operative complications**

# 7, 15% 41, 85% Image: Description of the second se

#### **Fig 13: Types of complications**



variables	Category	Frequency (n)	Percent (%)
Shape	poor	0	0
	Fair	3	6.4
	good	21	44.7
	excellent	23	48.9
Cleavage	poor	1	2.1
	Fair	4	8.5
	good	13	27.7
	excellent	29	61.7
Scar Visibility	poor	2	4.3
	Fair	15	31.9
	good	24	51.1
	excellent	6	12.8
Symmetry	poor	1	2.1
	Fair	5	10.6
	Good	27	57.4
	Excellent	14	29.8

#### Table 13: Cosmetic evaluation by 4 points Likert scale (n = 47)

- The median cosmesis score was 13 (Range: 6-16).
- Most of the patients (46, 97.9%) had a good to excellent (score 11 16) cosmesis.

Variable	Category by score	Frequenc y (n)	Percent (%)
Body image scale			
category	<80	9	18.8
	81-90	9	18.8
	90-100	30	62.5
Fear of			
recurrence category	0-40	2	4.2
	41-60	15	31.3
	60-70	8	16.7
	70-80	22	45.8
	80-90	1	2.1

#### Table 14: Quality of life scores in 100 (n = 48)

 Most of the patients (30, 62.5%) were highly satisfied with their body image with a score of 91-100.

 Twenty two patients (45.8%) were in 70-80 score range of fear of recurrence. But 25 patients were below 70 score with higher fear of recurrence.

Variable	Category by score	Frequency (n)	Percent (%)
	50	2	4.2
Satisfaction with treatment	75	23	➡ 47.9
	100	23 🗖	→ 47.9
	50	5	10.4
Cosmetic result	75	32	66.7
	100	11	22.9

#### Satisfaction with treatment

 46 patients - they will do the same treatment either certainly (47.9%) or probably (47.9%)

#### cosmetic result

- 22.9 % the treated breast
   resembles the opposite breast very
   much
- 66.7 % patients said that it is quite a bit similar

#### Table 16: Association between cosmesis and comorbidity

	Comorbidity		<b>Fishar's</b>	
Cosmesis	Νο	Yes	Fisher's	<i>p</i> -value
	(n=30)	(n=17)	Exact test	
Poor to fair	6 (20)	2 (11.11)	692	0 257 (NS)
Good to excellent	24 (80)	15 (83.33)	.052	0.237 (113)

# Table 17: Association between BMI category and post-operative complications

Post operation complications	BMI ca Underweight to normal (n=19)	ategory Overweight to obese (n=29)	Fisher's exact test	<i>p</i> -value
No Yes	17 (89.5) 2 (10 5)	24 (82.8) 5 (17 2)	.416	0.687 (NS)

#### Table 18: Association between preoperative T stage and cosmesis

Preoperative T stage	Poor to fair $(n-2)$	Good to excellent	Fisher's Exact test	<i>p</i> -value
	(n=8)	(n=39)		
T0 + T1	2 (25)	26 (66.6)	4 705 4	
T2 + T3	6 (75)	13 (33.3)	4.7854	.028
## Table 19: Association between NACT with post-operative complications

Dest enerative	Neoadjuvant treatment received			
Post-operative	No	Yes	χ² test	<i>p</i> -value
complications	(n=14)	(n=34)		
No	14 (100.0)	27 (79.4)	2 27/	
Yes	0 (0.0)	7 (20.6)	5.574	0.09 (113)

# Table 20: Association between post-operative complication and cosmesis

Cosmesis					
Post-operative	Poor to fair	Good to	2		
complications	(n=8)	excellent	χ <sup>2</sup> test	<i>p</i> -value	
		(n=39)			
Νο	5 (62.5)	36 (92.3)	E 2062	.021	
Yes	3 (37.5)	3 (7.7)	5.2905		

# Table 21: Association between post-operative complicationand body image

Dest energing	Body image			
Post-operative	<=96	>96	χ2 test	<i>p</i> -value
complication	(n=38)	(n=10)		
No	35 (65.8)	6 (50.0)	A 227	.039
Yes	3 (34.2)	4 (50.0)	7.221	

## Table 22 : Association between post-operative complication with fearof recurrence

Dest sussitive	QoL fear recurrence			
Post-operative	<=75	>75	χ² test	<i>p</i> -value
complication	(n=33)	(n=15)		
No	27 (81.8)	14(93.3)	0 3679	.544 (NS)
Yes	6 (1.8)	1 (6.6)		

## Conclusion

- OPS can be performed to different age group of patients, irrespective of receptor status, use of NACT, BMI and comorbidity with oncological safety in respect to margin clearance, acceptable postoperative pain and complications and excellent cosmetic outcome in short term.
- It has a positive impact on all aspects of QOL with a high patient satisfaction in respect to body image, fear of recurrence, treatment satisfaction and cosmetic result.

- There is significant association between post-operative complication and body image.
- Preoperative tumour size and post-operative complications are significantly associated with cosmetic outcome after OPS.
- It can be done by trained specialists, with a favourable outcome even in low resource settings in carefully selected patients.

#### European Journal of Surgical Oncology 49 (2023) e217-e270



Abstracts for oral presentation at the ABS Conference, 15th & 16th May 2023, ICC Belfast

#### P037

### SHORT TERM OUTCOMES OF ONCOPLASTIC BREAST SURGERY AT A TERTIARY CANCER CENTRE IN BANGLADESH

Hasan Shahriar Md. Nuruzzaman<sup>1</sup>, A K M Minhaj Uddin Bhuiyan<sup>1</sup>, Md. Johirul Islam<sup>1</sup>, Md. Zaker Ullah<sup>2</sup>. <sup>1</sup>National Institute of Cancer Research and Hospital, Dhaka, Bangladesh; <sup>2</sup> Barts Health NHS Trust, London, UK

**Introduction:** Oncoplastic breast surgery (OPS) is the preferred approach of treatment for many breast cancer patients with comparable surgical, oncological and survival outcomes. OPS has a huge potential in Bangladesh, but no study has been conducted to date to quantify the surgical, oncological, cosmetic, and quality of life (QoL) outcomes of OPS. **Methodology:** This was a prospective study conducted among 48 consecutive patients with breast cancer at National Institute of Cancer Research & Hospital, Dhaka, who met the inclusion criteria for OPS from March 2021 to June 2022. Multiple socio-demographic, tumour, surgical outcome, cosmesis and QoL related data were collected and analysed using SPSS.

**Result:** Most patients had T2 and N1 disease (79.2%), with a median age of 40 years. The mean pathological tumour size was 20.38 (11.54 mm). 15% of patients had post-operative complications. Most of them had a good to excellent cosmesis with a median score of 13. 62.5% were highly satisfied with their body image. Post-operative complication was associated with



European Journal of Surgical Oncology 49 (2023) e217-e270

body image (X<sup>2</sup>= 4.227 (df=1); p = 0.039). Cosmesis had significant association with pre-operative T stage (X<sup>2</sup> = 4.785 (df=1); p = 0.028) and post-operative complications (X<sup>2</sup>=5.296 (df=1); p = 0.021).

**Conclusion:** The study results suggest that OPS could be a feasible approach for Bangladeshi patients with a comparable surgical outcome, acceptable complication rate, excellent cosmesis and satisfactory quality of life, in short term, even in a resource-poor setting. Though, further randomised, multicentre studies with larger sample sizes and comparison groups are required to validate these findings.





# Thank you